Publications:31
- Home
- Profiles
Arvin Dar, PhD
- About Me
- Education & Certifications
- Awards
- Research
- Locations
- Publications
- Industry Relationships
About Me
Arvin Dar is a Professor in the Departments of Oncological Sciences and Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai, NYC. He is also the Associate Director of the Mount Sinai Center for Therapeutic Discovery and a member of the Tisch Cancer Institute (TCI). Dr. Dar’s research is focused on the integration of genetics and small molecule chemistry to uncover basic principles of signal transduction, with applications in tool development and therapeutics. His laboratory has been researching and developing kinase inhibitors and other small molecule approaches for the treatment of cancer and neurological disorders. Dr. Dar has received numerous awards and honors, including the NIH Director’s New Innovator Award, Damon-Runyon Rachleff Innovation Award, the Pew Charitable Trusts Pew-Stewart Scholarship for Cancer Research, Pershing Square Sohn Cancer Research Alliance Award, Junior Faculty Award at Mount Sinai, Friedman Brain Institute Scholar Award, and the Mark Foundation for Cancer Research Aspire Award.
Language
Position
Research Topics
Cancer, Drug Design and Discovery, Enzymology, Genetics, Protein Complexes, Structural Biology
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
About Me
Arvin Dar is a Professor in the Departments of Oncological Sciences and Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai, NYC. He is also the Associate Director of the Mount Sinai Center for Therapeutic Discovery and a member of the Tisch Cancer Institute (TCI). Dr. Dar’s research is focused on the integration of genetics and small molecule chemistry to uncover basic principles of signal transduction, with applications in tool development and therapeutics. His laboratory has been researching and developing kinase inhibitors and other small molecule approaches for the treatment of cancer and neurological disorders. Dr. Dar has received numerous awards and honors, including the NIH Director’s New Innovator Award, Damon-Runyon Rachleff Innovation Award, the Pew Charitable Trusts Pew-Stewart Scholarship for Cancer Research, Pershing Square Sohn Cancer Research Alliance Award, Junior Faculty Award at Mount Sinai, Friedman Brain Institute Scholar Award, and the Mark Foundation for Cancer Research Aspire Award.
Language
Position
Research Topics
Cancer, Drug Design and Discovery, Enzymology, Genetics, Protein Complexes, Structural Biology
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
About Me
Arvin Dar is a Professor in the Departments of Oncological Sciences and Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai, NYC. He is also the Associate Director of the Mount Sinai Center for Therapeutic Discovery and a member of the Tisch Cancer Institute (TCI). Dr. Dar’s research is focused on the integration of genetics and small molecule chemistry to uncover basic principles of signal transduction, with applications in tool development and therapeutics. His laboratory has been researching and developing kinase inhibitors and other small molecule approaches for the treatment of cancer and neurological disorders. Dr. Dar has received numerous awards and honors, including the NIH Director’s New Innovator Award, Damon-Runyon Rachleff Innovation Award, the Pew Charitable Trusts Pew-Stewart Scholarship for Cancer Research, Pershing Square Sohn Cancer Research Alliance Award, Junior Faculty Award at Mount Sinai, Friedman Brain Institute Scholar Award, and the Mark Foundation for Cancer Research Aspire Award.
Language
Position
Research Topics
Cancer, Drug Design and Discovery, Enzymology, Genetics, Protein Complexes, Structural Biology
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Education
BSc, University of Western Ontario
PhD, University of Toronto
Postdoctoral Training, University of California, San Francisco
Awards
2020
The Mark Foundation for Cancer Research ASPIRE Award
The Mark Foundation for Cancer Research
2018
Friedman Brain Institute Research Scholar
Friedman Brain Institute
2015
Pershing Square Sohn Prize for Young Investigators (PSSCRA)
Pershing Square
2014
Damon Runyon-Rachleff Innovation Award
Damon Runyon Cancer Research Foundation
2014
Pew-Stewart Scholar for Cancer Research
The Pew and Alexander and Margaret Stewart Charitable Trusts
2013
NIH Director’s New Innovator Award
National Institute of Health
2012
UCSF Dean's Postdoctoral Prize
UCSF
2012
Tisch Cancer Institute Developmental Fund Award
2006
BCRP Multidisciplinary Postdoctoral Award
US Department of Defense
2003
Canadian Graduate Scholarship
Canadian Institutes for Health Research
Research
Through the development and understanding of small molecules, our lab explores links between the regulation of drug targets and the system level properties of biological networks within cells and animals. Our goals are to create new tools to modulate and explore biomolecular function, with a long-term objective of developing innovative medicines for disease. Our work is highly interdisciplinary, employing methods from synthetic organic chemistry, X-ray crystallography, mass spectrometry, informatics, biochemistry and model organism genetics.
In one research area we are investigating one of the most frequently activated pathways in cancer biology: the Ras-Mitogen Activated Protein Kinase (MAPK) pathway. Oncogenic forms of Ras occur in over 20% of all cancers. These mutants have stifled direct pharmacological approaches and inhibitors for the direct effectors of Ras have shown limited or no efficacy in patients. We are exploring new targets or strategies to modulate the Ras pathway through the development of chemical tools. In particular, we are using target-based and systems pharmacology approaches to generate new classes of small molecule modulators for the Ras pathway.
Postdoctoral Fellows: Alex Scopton, Zaigham Khan, Jayasudhan Yerabolu
Current Students: Jia (Annie) Yu, Ryan Smith, Alexander Real, Arthur Chow
Research Assistant: Lisa Silber
Locations
Publications
Selected Publications
- WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Alex Rialdi, Mary Duffy, Alex P. Scopton, Frank Fonseca, Julia Nanyi Zhao, Megan Schwarz, Pedro Molina-Sanchez, Slim Mzoughi, Elisa Arceci, Jordi Abril-Fornaguera, Austin Meadows, Marina Ruiz de Galarreta, Denis Torre, Kyna Reyes, Yan Ting Lim, Felix Rosemann, Zaigham M. Khan, Kevin Mohammed, Xuedi Wang, Xufen Yu, Manikandan Lakshmanan, Ravisankar Rajarethinam, Soo Yong Tan, Jian Jin, Augusto Villanueva, Eleftherios Michailidis, Ype P. De Jong, Charles M. Rice, Ivan Marazzi, Dan Hasson, Josep M. Llovet, Radoslaw M. Sobota, Amaia Lujambio, Ernesto Guccione, Arvin C. Dar. Nature Cancer
- RASopathy mutations open new insights into the mechanism of BRAF activation. Arvin C. Dar, Donita C. Brady. Molecular Cell
- Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Megan Schwarz, Denis Torre, Daniel Lozano-Ojalvo, Anthony T. Tan, Tommaso Tabaglio, Slim Mzoughi, Rodrigo Sanchez-Tarjuelo, Nina Le Bert, Joey Ming Er Lim, Sandra Hatem, Kevin Tuballes, Carmen Camara, Eduardo Lopez-Granados, Estela Paz-Artal, Rafael Correa-Rocha, Alberto Ortiz, Marcos Lopez-Hoyos, Jose Portoles, Isabel Cervera, Maria Gonzalez-Perez, Irene Bodega-Mayor, Patricia Conde, Jesús Oteo-Iglesias, Alberto M. Borobia, Antonio J. Carcas, Jesús Frías, Cristóbal Belda-Iniesta, Jessica S.Y. Ho, Kemuel Nunez, Saboor Hekmaty, Kevin Mohammed, William M. Marsiglia, Juan Manuel Carreño, Arvin C. Dar, Cecilia Berin, Giuseppe Nicoletti, Isabella Della Noce, Lorenzo Colombo, Cristina Lapucci, Graziano Santoro, Maurizio Ferrari, Kai Nie, Manishkumar Patel, Vanessa Barcessat, Sacha Gnjatic, Jocelyn Harris, Robert Sebra, Miriam Merad, Florian Krammer, Seunghee Kim-schulze, Ivan Marazzi, Antonio Bertoletti, Jordi Ochando, Ernesto Guccione. Nature Biotechnology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Dar during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- Nested Therapeutics
- Prometeo Therapeutics
Consulting:
- Nested Therapeutics
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Nested Therapeutics
Royalty Payments:
- Nested Therapeutics
Scientific Advisory Board:
- Nested Therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.